HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesNew pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and fluCriteria for drugs used in pre-exposure prophylaxis trials against HIV infectionNucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutationCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CMonitoring HIV viral load in resource limited settings: still a matter of debate?High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaTrends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, MozambiqueHIV-1 Variants and Drug Resistance in Pregnant Women from Bata (Equatorial Guinea): 2012-2013Recent Insights into the HIV/AIDS Pandemic.HIV-1 drug resistance and resistance testing.HIV-1 Genetic Variability and Clinical ImplicationsHIV-1 genetic variation and drug resistance development.Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapyPotential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsTheme and variations in the evolutionary pathways to virulence of an RNA plant virus species.Antiretroviral therapy for prevention of HIV infection: new clues from an animal model.The HIV-1 subtype C epidemic in South America is linked to the United Kingdom.Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaA national study of the molecular epidemiology of HIV-1 in Australia 2005-2012The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingFemale genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau.High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programmeSubtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.
P2860
Q26851997-E4BD5DC5-D745-465C-96FC-AB2DC5E7B19BQ27478093-18C4775E-87F0-4099-8E8C-B5C29C239F23Q28469067-BD646EFF-5DD2-4A27-9B0D-4ABD3B609309Q28474274-F4466869-03FD-4FB1-B157-27D1BE9CFFFEQ28482138-C9E60747-3922-43B4-991A-66311ED6632EQ28484213-F13AB0AC-EE61-470F-A3C8-D4B27056D1FCQ28485511-FF1166FA-4078-4CAC-AE1A-749976329C82Q28543358-596824DB-2BE0-4773-99CA-1F29ABB69BF5Q28546341-CD613EE9-AF3C-4C21-8B03-3A8D49698F8EQ28553083-A52084F4-33F6-4AC2-88FA-D182D69DBD0BQ30235024-7A6AA6A6-686A-4B4F-9519-D1B16BFC43CCQ30245693-8E055621-EA4C-4B7D-B324-290C71628C39Q30352010-86C5406B-1243-4980-9583-801B3A4A20CAQ30354857-FAF0D212-6528-47ED-9738-9FE46A758C45Q30394627-E089C7B1-B591-49C4-A5CA-0297F539D1CFQ30395110-48BEF70B-E7DA-4E94-9A6F-6CA35A8A5317Q33299456-C606618B-7381-4953-911C-1D06F2DE266FQ33307185-2C28065D-FEEB-4DAC-A617-67264326F61EQ33318541-CE2978B6-9876-4310-948D-D6A157252914Q33533291-070FB9BC-053E-4E22-B27F-1FAC74783888Q33625367-689ABAA8-A0F5-45A0-A481-E35460221FF8Q33657146-7E7692C9-3A92-4730-AC2D-A7FC42DF7FB9Q33681279-BC214191-DB64-43B9-AFBC-A6BD4E8DF132Q33714130-AFF28CFF-A4D2-4D4C-841B-776BBF67B227Q33927293-07500A63-50DD-4C5A-A0B8-2BB89CC2A443Q33959260-2E5E208D-1C61-4986-8E21-4FD8D839AAB8Q34136227-8C5E37C0-B983-47A2-B4F9-2BCC0862AE20Q34243467-65C91602-B958-4630-9D65-C04934557568Q34303603-5CABF7A3-109F-40CE-9DA7-B91DE60DA0E5Q34529310-92B7AB67-654E-4924-B266-96E1327D6855Q34567556-A5C55482-63E1-4DD3-82DB-B0B29E7A7CA1Q34680240-86023BA7-E9CF-45E1-868B-F8C57EF99CFAQ34933329-AFBDC758-4A18-4BFA-B45F-7BCA078B70A1Q35170089-9F6A43A6-0D7D-4967-8941-E551B02AB279Q35215399-F9A32ADC-39FB-4007-8E60-928DA3E2EE7AQ35237036-91669325-880A-4449-8B5B-434BD2BCEEE0Q35260403-C1DBF516-9CA7-43D0-ADD5-162ECB4E342FQ35260590-4D26797A-EF47-4CA7-921B-5ED151EB46F8Q35536296-2DF5B344-CF5F-4B10-A20E-AC88C372D631Q35607740-718D6271-5FEA-4BC4-BF6F-EC418562F67E
P2860
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
@en
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
@nl
type
label
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
@en
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
@nl
prefLabel
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
@en
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
@nl
P2093
P1433
P1476
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
@en
P2093
Bluma G Brenner
Daniela D Moisi
Fernando Frankel
Florence Doualla-Bell
Mark A Wainberg
Maureen Oliveira
P356
10.1097/01.AIDS.0000232228.88511.0B
P407
P577
2006-06-01T00:00:00Z